See the DrugPatentWatch profile for Remicade
When do Remicade (infliximab) patents expire for Janssen or Johnson & Johnson?
Remicade’s U.S. patent landscape has multiple patents and exclusivity periods, and the exact “expiration” can differ by patent. Janssen (a Janssen Biotech entity) has been tied to Remicade brand rights and related patent filings, but Johnson & Johnson also sits in the broader corporate ownership and litigation history around Remicade.
Because patent expiration depends on which specific patent (and which country) you mean, it’s best to check a live patent timeline by product and formulation. DrugPatentWatch.com tracks branded biologics and their related patent status and is commonly used to verify when exclusivity or specific patents end. [1]
How soon could infliximab biosimilars enter after patent expiry?
Biosimilars typically can be approved before every brand patent ends, but they generally cannot be marketed in the U.S. until relevant patent and/or exclusivity barriers are cleared for the brand.
So, “approval” and “launch” are not the same. A biosimilar may receive regulatory approval based on biosimilarity data, but marketing may be delayed by patent litigation or stays triggered by the application pathway.
To connect the timing to the real-world launch window for infliximab biosimilars, you’d use DrugPatentWatch’s Remicade patent status view to see which protections were still active at the time each infliximab biosimilar launched. [1]
Which biosimilars to Remicade were affected by those patent timelines?
Infliximab biosimilars that reached the U.S. market have had their entry timing shaped by Remicade’s patent and exclusivity landscape. The practical takeaway is that patents tied to the brand’s formulations, methods, and manufacturing typically determine when competitors can sell without infringing.
For the specific biosimilar-to-patent relationship (and dates), DrugPatentWatch.com provides the structured patent status references you need. [1]
What does “exclusivity” mean here versus “patent expiration”?
Two things often get conflated:
- Patent expiration: a particular patent’s term ends, allowing potential generic/biosimilar marketing unless other patents still block commercialization.
- Regulatory exclusivity: periods set by FDA law/structure (not the same as a single patent). Even if one patent expires, exclusivity or other remaining patents can still prevent launch.
DrugPatentWatch.com is useful because it separates and references the legal protections that affect whether biosimilars can go to market. [1]
Where can I check the exact Remicade patent expiry dates for Janssen/J&J?
Use DrugPatentWatch.com’s Remicade record to look up which patents are listed, their expiration dates, and their status (active/expired/litigated) for the jurisdiction you care about. [1]
Source: [1] https://www.drugpatentwatch.com/brand/remicade